BSH 2024 | An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten, MBChB, MRCP, FRCPath, PhD, King’s College London, London, UK, introduces an ongoing Phase I/II trial (NCT04277637) investigating a combination therapy of zanubrutinib and sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The combination has been well tolerated, and early efficacy data have been encouraging, with no patients progressing at 9.7 months. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So the study that I’m presenting here at the British Society of Hematology meeting is looking at the combination of a second-generation BTK inhibitor, that’s zanubrutinib, and that’s given in combination with sonrotoclax, which is now a second-line BCL2 inhibitor. And we’ve seen in trials that have been done to date how successful pairing up ibrutinib and venetoclax together has been in treating CLL...
So the study that I’m presenting here at the British Society of Hematology meeting is looking at the combination of a second-generation BTK inhibitor, that’s zanubrutinib, and that’s given in combination with sonrotoclax, which is now a second-line BCL2 inhibitor. And we’ve seen in trials that have been done to date how successful pairing up ibrutinib and venetoclax together has been in treating CLL. But now we’ve got this opportunity to look at the data from a combination with newer second-line agents, which seems to be really, really effective and also very, very tolerable. So, patients are managing that treatment really nicely. The data is quite early, but it’s looking extremely promising and very impressive progression-free survival curve – in fact no patients at all have progressed at 9.7 months. And very tolerable, side effects are certainly not more than what we might expect and actually, I think patients are getting on with it really well. So I think it’s a really exciting study to be involved with.
Read more...
